PMID- 25073735
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20220410
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 9
DP  - 2014 Sep
TI  - Cardiovascular and ocular safety of alpha1-adrenoceptor antagonists in the treatment 
      of male lower urinary tract symptoms.
PG  - 1187-97
LID - 10.1517/14740338.2014.936376 [doi]
AB  - INTRODUCTION: alpha1-Adrenoceptor antagonists (alpha-blockers) represent first-line drug 
      treatment for male lower urinary tract symptoms. Their adverse events (AEs) 
      include asthenia, dizziness, nasal congestion, arterial (orthostatic) hypotension 
      and intraoperative floppy iris syndrome (IFIS). AREAS COVERED: This report 
      focuses on cardiovascular and ocular AEs of alpha-blockers as related to their 
      mechanism of action and subtype selectivity. EXPERT OPINION: The incidence of 
      hypotension differs between alpha-blockers. It is greatest with doxazosin or 
      terazosin, but others including tamsulosin can also lead to hypotension 
      especially upon treatment initiation. Concomitant antihypertensive medication 
      increases the incidence of hypotension with some alpha-blockers. Use of 
      alpha(1A)-selective blockers, evening dosing and drug intake after a meal can reduce 
      the risk of hypotension. IFIS can occur with all drugs exerting alpha(1)-adrenoceptor 
      antagonist properties and has especially been reported for tamsulosin. It makes 
      cataract surgery more challenging but does not constitute a health risk to 
      patients. IFIS seems to result from inhibition of iris dilator muscle contraction 
      and occurs in men or women, even after alpha-blockers have been discontinued. To 
      reduce the risk of IFIS, the authors suggest taking a careful drug history, 
      postponing alpha-blocker treatment for patients with scheduled cataract surgery and 
      careful counseling of patients taking alpha-blockers.
FAU - Oelke, Matthias
AU  - Oelke M
AD  - Hannover Medical School, Department of Urology , Hannover , Germany.
FAU - Gericke, Adrian
AU  - Gericke A
FAU - Michel, Martin C
AU  - Michel MC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20140729
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Adrenergic alpha-1 Receptor Antagonists)
SB  - IM
MH  - Adrenergic alpha-1 Receptor Antagonists/*adverse effects/therapeutic use
MH  - Animals
MH  - Cardiovascular Diseases/*chemically induced/physiopathology
MH  - Cataract Extraction/methods
MH  - Eye Diseases/*chemically induced/physiopathology
MH  - Female
MH  - Humans
MH  - Lower Urinary Tract Symptoms/drug therapy
MH  - Male
MH  - Patient Education as Topic
OTO - NOTNLM
OT  - adverse drug event
OT  - alfuzosin
OT  - blood pressure
OT  - doxazosin
OT  - hypotension
OT  - intraoperative floppy iris syndrome
OT  - silodosin
OT  - tamsulosin
OT  - terazosin
OT  - alpha1-adrenoceptor antagonist
EDAT- 2014/07/31 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/07/31 06:00
PHST- 2014/07/31 06:00 [entrez]
PHST- 2014/07/31 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - 10.1517/14740338.2014.936376 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Sep;13(9):1187-97. doi: 10.1517/14740338.2014.936376. 
      Epub 2014 Jul 29.